{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":null,"value":72},{"name":null,"value":26},{"name":null,"value":40},{"name":null,"value":27},{"name":null,"value":80},{"name":null,"value":28},{"name":null,"value":35},{"name":null,"value":10},{"name":null,"value":134},{"name":null,"value":121},{"name":null,"value":78},{"name":null,"value":29},{"name":null,"value":32},{"name":null,"value":31},{"name":null,"value":33},{"name":null,"value":126},{"name":"Real Estate","value":36},{"name":null,"value":82},{"name":null,"value":37},{"name":null,"value":115},{"name":"Government Matters","value":"cg-2"},{"name":null,"value":1},{"name":null,"value":6},{"name":null,"value":71},{"name":null,"value":21},{"name":null,"value":23},{"name":null,"value":116},{"name":null,"value":24},{"name":null,"value":135},{"name":null,"value":25},{"name":null,"value":110},{"name":null,"value":20},{"name":null,"value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":null,"value":129},{"name":null,"value":2},{"name":null,"value":38},{"name":null,"value":3},{"name":null,"value":5},{"name":null,"value":19},{"name":null,"value":7},{"name":null,"value":4},{"name":null,"value":136},{"name":null,"value":13},{"name":null,"value":14},{"name":null,"value":15},{"name":null,"value":17},{"name":null,"value":18},{"name":null,"value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":null,"value":133},{"name":null,"value":106},{"name":null,"value":124},{"name":null,"value":111},{"name":null,"value":132},{"name":null,"value":131},{"name":null,"value":102},{"name":null,"value":125},{"name":null,"value":127},{"name":null,"value":107},{"name":null,"value":112},{"name":null,"value":105},{"name":null,"value":109},{"name":null,"value":103},{"name":null,"value":128},{"name":null,"value":123},{"name":null,"value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"24","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"D","per_page":12,"people":[{"id":442361,"version":1,"owner_type":"Person","owner_id":853,"payload":{"bio":"\u003cp\u003eTodd Davis is a partner with King \u0026amp; Spalding's Trial \u0026amp; Global Disputes practice group. For the last twenty-eight years, Mr. Davis' practice has been devoted to trying high-stakes products liability cases, including those involving medications, medical devices and consumer products.\u0026nbsp; His involvement includes cross-examining plaintiffs\u0026rsquo; key causation and medical expert witnesses at trial and in deposition. \u0026nbsp;Mr. Davis\u0026rsquo; practice\u0026nbsp;involves representing pharmaceutical and medical device companies, as well as other product manufacturers, in mass tort, consumer fraud and class action litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Davis has been recognized in Legal 500\u0026rsquo;s Product Liability and Mass Tort Defense in the Pharma and Medical Device category.\u003c/p\u003e","slug":"todd-davis","email":"tdavis@kslaw.com","phone":null,"matters":["\u003cp\u003eTrying three cases for\u0026nbsp;\u003cstrong\u003eGlaxoSmithKline\u003c/strong\u003e\u0026nbsp;in the Philadelphia Court of Common Pleas, Pennsylvania, alleging that Paxil causes birth defects (2016, 2010, 2009). In two trials, the courts dismissed plaintiffs' claims because plaintiffs could not prove proximate causation. In the third, which was plaintiffs' No. 1 pick for trial, plaintiffs were awarded compensatory damages less than the actual medical expenses incurred and no punitive damages.\u003c/p\u003e","\u003cp\u003eTrying the first \u0026ldquo;innovator liability\u0026rdquo; prescription drug case to go to trial (\u003cem\u003eDolin v. GSK,\u0026nbsp;\u003c/em\u003e2017\u003cem\u003e).\u003c/em\u003e\u003c/p\u003e","\u003cp\u003eTrying cases for R.J. Reynolds Tobacco Company as part of the\u0026nbsp;\u003cem\u003eEngle\u003c/em\u003e-progeny litigation in Florida (2013, 2014, 2018, 2019 and 2020).\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003emedical device and pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in federal multi-district litigation and state consolidated proceedings. Defeating efforts to certify a\u0026nbsp;\u003cstrong\u003enationwide class\u003c/strong\u003e\u0026nbsp;of Paxil users under personal injury and consumer fraud theories.\u0026nbsp;\u003cem\u003eIn re Paxil,\u003c/em\u003e\u0026nbsp;212 F.R.D. 539 (C.D. Cal. 2003). This decision has been referred to as one of the \u0026ldquo;Big Four\u0026rdquo; federal court rulings denying class certification in pharmaceutical cases.\u0026nbsp;\u003cem\u003eSee\u003c/em\u003e\u0026nbsp;\u003cem\u003eIn\u003c/em\u003e\u0026nbsp;\u003cem\u003ere\u003c/em\u003e\u0026nbsp;\u003cem\u003ePrempro\u003c/em\u003e\u0026nbsp;\u003cem\u003eProds. Liab. Lit.\u003c/em\u003e, 230 F.R.D. 555 (E.D. Ark. 2005).\u003c/p\u003e","\u003cp\u003eDefeating efforts to certify\u0026nbsp;\u003cstrong\u003ea statewide claim\u003c/strong\u003e\u0026nbsp;of Paxil users under California\u0026rsquo;s Unfair Competition Law, \u0026sect; 17200\u003cem\u003e.\u003c/em\u003e\u0026nbsp;\u003cem\u003eIn re Paxil,\u003c/em\u003e\u0026nbsp;218 F.R.D. 242 (C.D. Cal. 2003).\u003c/p\u003e","\u003cp\u003eDefeating efforts to certify a\u0026nbsp;\u003cstrong\u003enationwide class\u003c/strong\u003e\u0026nbsp;of pediatric patients who were prescribed a medication not approved by the FDA to treat patients under 18.\u0026nbsp;\u003cem\u003ePamela Blain, et al. v. SmithKline Beecham Corp\u003c/em\u003e., 240 F.R.D. 179 (E.D. Pa. 2007).\u003c/p\u003e","\u003cp\u003eObtaining summary judgments based on federal preemption of state law\u0026nbsp;\u003cstrong\u003efailure-to-warn claims\u003c/strong\u003e\u0026nbsp;in cases involving a prescription medication.\u0026nbsp;\u003cem\u003eE.g., O\u0026rsquo;Neal v. SmithKline Beecham Corp.\u003c/em\u003e, 551 F.Supp.2d 993 (E.D. Cal. 2008);\u0026nbsp;\u003cem\u003eCandace Miller et al v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline\u003c/em\u003e, slip op., 2008 WL 510449 (N.D. Okla).\u003c/p\u003e","\u003cp\u003eSuccessfully excluding plaintiff\u0026rsquo;s experts\u0026rsquo; opinions that breast implants cause systemic illness on\u0026nbsp;\u003cstrong\u003e\u003cem\u003eDaubert\u003c/em\u003e\u0026nbsp;grounds\u003c/strong\u003e\u0026nbsp;in the first breast implant case set for trial in Georgia. Mr. Davis successfully defended that decision on appeal in the first federal appellate decision in the country addressing\u0026nbsp;\u003cem\u003eDaubert\u003c/em\u003e\u0026nbsp;issues in the breast implant litigation.\u0026nbsp;\u003cem\u003eAllison v. McGhan Medical Corp.\u003c/em\u003e\u0026nbsp;184 F.3d 1300 (11th Cir. 1999).\u003c/p\u003e","\u003cp\u003eSuccessfully defending\u0026nbsp;\u003cstrong\u003ea product liability lawsuit\u003c/strong\u003e\u0026nbsp;filed in the \u0026ldquo;rocket-docket\u0026rdquo; of the U.S.D.C., Eastern District of Virginia that involved allegations that a uniformed officer of the Secret Service committed murder and then suicide because of a prescription medication. After an intensive 2-1/2 month discovery period, plaintiff dismissed his lawsuit on the eve of trial. The defendant paid nothing in settlement.\u003c/p\u003e","\u003cp\u003eSuccessfully defending on appeal summary judgment for\u0026nbsp;\u003cstrong\u003ea pharmaceutical manufacturer\u003c/strong\u003e\u0026nbsp;based upon the learned intermediary doctrine.\u0026nbsp;\u003cem\u003eAllgood v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline\u003c/em\u003e, No. 06-cv-3506, 2008 WL 483574 (E.D. La. Feb. 20, 2008),\u0026nbsp;\u003cem\u003eaff\u0026rsquo;d by\u003c/em\u003e\u0026nbsp;No. 08- 30329, 2009 WL 646285 (5th Cir. Mar. 13, 2009),\u0026nbsp;\u003cem\u003ereh\u0026rsquo;g denied by\u003c/em\u003e\u0026nbsp;No. 08-30329 (5th Cir. May 6, 2009).\u003c/p\u003e","\u003cp\u003eObtaining summary judgment in\u0026nbsp;\u003cstrong\u003ea product liability lawsuit\u003c/strong\u003e\u0026nbsp;involving a prescription medication within four months after plaintiff filed his lawsuit,\u0026nbsp;\u003cem\u003eHoward v. GlaxoSmithKline\u003c/em\u003e, Case No. 05-1525 (U.S.D.C., E.D. Cal.)\u0026nbsp;\u003cem\u003eaff\u0026rsquo;d\u003c/em\u003e\u0026nbsp;(9th Cir. 2007), and obtaining summary judgments in two product liability wrongful death lawsuits when plaintiffs\u0026rsquo; claimed they did not timely file their lawsuit because of the defendant\u0026rsquo;s \u0026ldquo;fraudulent concealment.\u0026rdquo;\u0026nbsp;\u003cem\u003ePamela Blain, et al., v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline\u003c/em\u003e, Civil Action No. 07-1157- MLB-DWB (U.S.D.C., D. Kan.);\u0026nbsp;\u003cem\u003eCollins v. SmithKlineBeecham Corp.,\u003c/em\u003e\u0026nbsp;Philadelphia Court of Common Pleas, Pennsylvania,\u0026nbsp;\u003cem\u003eaff'd\u003c/em\u003e\u0026nbsp;on appeal.\u003c/p\u003e","\u003cp\u003eManaging massive electronic discovery and hard copy productions and coordinating discovery of plaintiffs\u0026rsquo; claims.\u003c/p\u003e","\u003cp\u003eSuccessfully defending against motions to compel that sought thousands of privileged documents in\u0026nbsp;\u003cstrong\u003epersonal injury lawsuits\u003c/strong\u003e\u0026nbsp;involving prescription medications.\u003c/p\u003e","\u003cp\u003eMajor responsibility in\u0026nbsp;\u003cstrong\u003eseveral hundred breast implant cases\u003c/strong\u003e\u0026nbsp;in Georgia, Florida, Alabama, Mississippi, Tennessee, South Carolina, North Carolina, Virginia and the District of Columbia. Mr. Davis second-chaired the trial of the first breast implant case tried in Tennessee. The trial lasted five-and-a-half weeks and included claims of both local and systemic injury. The jury returned a defense verdict.\u003c/p\u003e","\u003cp\u003eSuccessfully arguing for\u0026nbsp;\u003cstrong\u003etransfer of a host of cases\u003c/strong\u003e\u0026nbsp;to the plaintiffs\u0026rsquo; home states under 28 U.S.C. \u0026sect; 1404. (Plaintiffs attempted to bring their lawsuits in the state of the pharmaceutical company\u0026rsquo;s business office as opposed to the states of their residence.)\u003c/p\u003e","\u003cp\u003eDefending\u0026nbsp;\u003cstrong\u003ehigh-ranking company executives\u003c/strong\u003e\u0026nbsp;in depositions.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ea manufacturer\u003c/strong\u003e\u0026nbsp;in an emergency appeal of an order allowing plaintiffs to depose the manufacturer\u0026rsquo;s in-house litigation counsel. In an appeal to the Kentucky Supreme Court, Mr. Davis successfully argued for reversal of the trial court\u0026rsquo;s order.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":63}]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":17,"guid":"17.capabilities","index":1,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":2,"source":"smartTags"},{"id":764,"guid":"764.smart_tags","index":3,"source":"smartTags"},{"id":3,"guid":"3.capabilities","index":4,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":5,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":6,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":7,"source":"capabilities"},{"id":16,"guid":"16.capabilities","index":8,"source":"capabilities"},{"id":112,"guid":"112.capabilities","index":9,"source":"capabilities"}],"is_active":true,"last_name":"Davis","nick_name":"Todd","clerkships":[],"first_name":"Todd","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":"P.","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eTodd Davis is a partner with King \u0026amp; Spalding's Trial \u0026amp; Global Disputes practice group. For the last twenty-eight years, Mr. Davis' practice has been devoted to trying high-stakes products liability cases, including those involving medications, medical devices and consumer products.\u0026nbsp; His involvement includes cross-examining plaintiffs\u0026rsquo; key causation and medical expert witnesses at trial and in deposition. \u0026nbsp;Mr. Davis\u0026rsquo; practice\u0026nbsp;involves representing pharmaceutical and medical device companies, as well as other product manufacturers, in mass tort, consumer fraud and class action litigation.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Davis has been recognized in Legal 500\u0026rsquo;s Product Liability and Mass Tort Defense in the Pharma and Medical Device category.\u003c/p\u003e","matters":["\u003cp\u003eTrying three cases for\u0026nbsp;\u003cstrong\u003eGlaxoSmithKline\u003c/strong\u003e\u0026nbsp;in the Philadelphia Court of Common Pleas, Pennsylvania, alleging that Paxil causes birth defects (2016, 2010, 2009). In two trials, the courts dismissed plaintiffs' claims because plaintiffs could not prove proximate causation. In the third, which was plaintiffs' No. 1 pick for trial, plaintiffs were awarded compensatory damages less than the actual medical expenses incurred and no punitive damages.\u003c/p\u003e","\u003cp\u003eTrying the first \u0026ldquo;innovator liability\u0026rdquo; prescription drug case to go to trial (\u003cem\u003eDolin v. GSK,\u0026nbsp;\u003c/em\u003e2017\u003cem\u003e).\u003c/em\u003e\u003c/p\u003e","\u003cp\u003eTrying cases for R.J. Reynolds Tobacco Company as part of the\u0026nbsp;\u003cem\u003eEngle\u003c/em\u003e-progeny litigation in Florida (2013, 2014, 2018, 2019 and 2020).\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003emedical device and pharmaceutical companies\u003c/strong\u003e\u0026nbsp;in federal multi-district litigation and state consolidated proceedings. Defeating efforts to certify a\u0026nbsp;\u003cstrong\u003enationwide class\u003c/strong\u003e\u0026nbsp;of Paxil users under personal injury and consumer fraud theories.\u0026nbsp;\u003cem\u003eIn re Paxil,\u003c/em\u003e\u0026nbsp;212 F.R.D. 539 (C.D. Cal. 2003). This decision has been referred to as one of the \u0026ldquo;Big Four\u0026rdquo; federal court rulings denying class certification in pharmaceutical cases.\u0026nbsp;\u003cem\u003eSee\u003c/em\u003e\u0026nbsp;\u003cem\u003eIn\u003c/em\u003e\u0026nbsp;\u003cem\u003ere\u003c/em\u003e\u0026nbsp;\u003cem\u003ePrempro\u003c/em\u003e\u0026nbsp;\u003cem\u003eProds. Liab. Lit.\u003c/em\u003e, 230 F.R.D. 555 (E.D. Ark. 2005).\u003c/p\u003e","\u003cp\u003eDefeating efforts to certify\u0026nbsp;\u003cstrong\u003ea statewide claim\u003c/strong\u003e\u0026nbsp;of Paxil users under California\u0026rsquo;s Unfair Competition Law, \u0026sect; 17200\u003cem\u003e.\u003c/em\u003e\u0026nbsp;\u003cem\u003eIn re Paxil,\u003c/em\u003e\u0026nbsp;218 F.R.D. 242 (C.D. Cal. 2003).\u003c/p\u003e","\u003cp\u003eDefeating efforts to certify a\u0026nbsp;\u003cstrong\u003enationwide class\u003c/strong\u003e\u0026nbsp;of pediatric patients who were prescribed a medication not approved by the FDA to treat patients under 18.\u0026nbsp;\u003cem\u003ePamela Blain, et al. v. SmithKline Beecham Corp\u003c/em\u003e., 240 F.R.D. 179 (E.D. Pa. 2007).\u003c/p\u003e","\u003cp\u003eObtaining summary judgments based on federal preemption of state law\u0026nbsp;\u003cstrong\u003efailure-to-warn claims\u003c/strong\u003e\u0026nbsp;in cases involving a prescription medication.\u0026nbsp;\u003cem\u003eE.g., O\u0026rsquo;Neal v. SmithKline Beecham Corp.\u003c/em\u003e, 551 F.Supp.2d 993 (E.D. Cal. 2008);\u0026nbsp;\u003cem\u003eCandace Miller et al v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline\u003c/em\u003e, slip op., 2008 WL 510449 (N.D. Okla).\u003c/p\u003e","\u003cp\u003eSuccessfully excluding plaintiff\u0026rsquo;s experts\u0026rsquo; opinions that breast implants cause systemic illness on\u0026nbsp;\u003cstrong\u003e\u003cem\u003eDaubert\u003c/em\u003e\u0026nbsp;grounds\u003c/strong\u003e\u0026nbsp;in the first breast implant case set for trial in Georgia. Mr. Davis successfully defended that decision on appeal in the first federal appellate decision in the country addressing\u0026nbsp;\u003cem\u003eDaubert\u003c/em\u003e\u0026nbsp;issues in the breast implant litigation.\u0026nbsp;\u003cem\u003eAllison v. McGhan Medical Corp.\u003c/em\u003e\u0026nbsp;184 F.3d 1300 (11th Cir. 1999).\u003c/p\u003e","\u003cp\u003eSuccessfully defending\u0026nbsp;\u003cstrong\u003ea product liability lawsuit\u003c/strong\u003e\u0026nbsp;filed in the \u0026ldquo;rocket-docket\u0026rdquo; of the U.S.D.C., Eastern District of Virginia that involved allegations that a uniformed officer of the Secret Service committed murder and then suicide because of a prescription medication. After an intensive 2-1/2 month discovery period, plaintiff dismissed his lawsuit on the eve of trial. The defendant paid nothing in settlement.\u003c/p\u003e","\u003cp\u003eSuccessfully defending on appeal summary judgment for\u0026nbsp;\u003cstrong\u003ea pharmaceutical manufacturer\u003c/strong\u003e\u0026nbsp;based upon the learned intermediary doctrine.\u0026nbsp;\u003cem\u003eAllgood v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline\u003c/em\u003e, No. 06-cv-3506, 2008 WL 483574 (E.D. La. Feb. 20, 2008),\u0026nbsp;\u003cem\u003eaff\u0026rsquo;d by\u003c/em\u003e\u0026nbsp;No. 08- 30329, 2009 WL 646285 (5th Cir. Mar. 13, 2009),\u0026nbsp;\u003cem\u003ereh\u0026rsquo;g denied by\u003c/em\u003e\u0026nbsp;No. 08-30329 (5th Cir. May 6, 2009).\u003c/p\u003e","\u003cp\u003eObtaining summary judgment in\u0026nbsp;\u003cstrong\u003ea product liability lawsuit\u003c/strong\u003e\u0026nbsp;involving a prescription medication within four months after plaintiff filed his lawsuit,\u0026nbsp;\u003cem\u003eHoward v. GlaxoSmithKline\u003c/em\u003e, Case No. 05-1525 (U.S.D.C., E.D. Cal.)\u0026nbsp;\u003cem\u003eaff\u0026rsquo;d\u003c/em\u003e\u0026nbsp;(9th Cir. 2007), and obtaining summary judgments in two product liability wrongful death lawsuits when plaintiffs\u0026rsquo; claimed they did not timely file their lawsuit because of the defendant\u0026rsquo;s \u0026ldquo;fraudulent concealment.\u0026rdquo;\u0026nbsp;\u003cem\u003ePamela Blain, et al., v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline\u003c/em\u003e, Civil Action No. 07-1157- MLB-DWB (U.S.D.C., D. Kan.);\u0026nbsp;\u003cem\u003eCollins v. SmithKlineBeecham Corp.,\u003c/em\u003e\u0026nbsp;Philadelphia Court of Common Pleas, Pennsylvania,\u0026nbsp;\u003cem\u003eaff'd\u003c/em\u003e\u0026nbsp;on appeal.\u003c/p\u003e","\u003cp\u003eManaging massive electronic discovery and hard copy productions and coordinating discovery of plaintiffs\u0026rsquo; claims.\u003c/p\u003e","\u003cp\u003eSuccessfully defending against motions to compel that sought thousands of privileged documents in\u0026nbsp;\u003cstrong\u003epersonal injury lawsuits\u003c/strong\u003e\u0026nbsp;involving prescription medications.\u003c/p\u003e","\u003cp\u003eMajor responsibility in\u0026nbsp;\u003cstrong\u003eseveral hundred breast implant cases\u003c/strong\u003e\u0026nbsp;in Georgia, Florida, Alabama, Mississippi, Tennessee, South Carolina, North Carolina, Virginia and the District of Columbia. Mr. Davis second-chaired the trial of the first breast implant case tried in Tennessee. The trial lasted five-and-a-half weeks and included claims of both local and systemic injury. The jury returned a defense verdict.\u003c/p\u003e","\u003cp\u003eSuccessfully arguing for\u0026nbsp;\u003cstrong\u003etransfer of a host of cases\u003c/strong\u003e\u0026nbsp;to the plaintiffs\u0026rsquo; home states under 28 U.S.C. \u0026sect; 1404. (Plaintiffs attempted to bring their lawsuits in the state of the pharmaceutical company\u0026rsquo;s business office as opposed to the states of their residence.)\u003c/p\u003e","\u003cp\u003eDefending\u0026nbsp;\u003cstrong\u003ehigh-ranking company executives\u003c/strong\u003e\u0026nbsp;in depositions.\u003c/p\u003e","\u003cp\u003eRepresenting\u0026nbsp;\u003cstrong\u003ea manufacturer\u003c/strong\u003e\u0026nbsp;in an emergency appeal of an order allowing plaintiffs to depose the manufacturer\u0026rsquo;s in-house litigation counsel. In an appeal to the Kentucky Supreme Court, Mr. Davis successfully argued for reversal of the trial court\u0026rsquo;s order.\u003c/p\u003e"]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":805}]},"capability_group_id":3},"created_at":"2025-11-05T05:03:30.000Z","updated_at":"2025-11-05T05:03:30.000Z","searchable_text":"Davis{{ FIELD }}Trying three cases for GlaxoSmithKline in the Philadelphia Court of Common Pleas, Pennsylvania, alleging that Paxil causes birth defects (2016, 2010, 2009). In two trials, the courts dismissed plaintiffs' claims because plaintiffs could not prove proximate causation. In the third, which was plaintiffs' No. 1 pick for trial, plaintiffs were awarded compensatory damages less than the actual medical expenses incurred and no punitive damages.{{ FIELD }}Trying the first “innovator liability” prescription drug case to go to trial (Dolin v. GSK, 2017).{{ FIELD }}Trying cases for R.J. Reynolds Tobacco Company as part of the Engle-progeny litigation in Florida (2013, 2014, 2018, 2019 and 2020).{{ FIELD }}Representing medical device and pharmaceutical companies in federal multi-district litigation and state consolidated proceedings. Defeating efforts to certify a nationwide class of Paxil users under personal injury and consumer fraud theories. In re Paxil, 212 F.R.D. 539 (C.D. Cal. 2003). This decision has been referred to as one of the “Big Four” federal court rulings denying class certification in pharmaceutical cases. See In re Prempro Prods. Liab. Lit., 230 F.R.D. 555 (E.D. Ark. 2005).{{ FIELD }}Defeating efforts to certify a statewide claim of Paxil users under California’s Unfair Competition Law, § 17200. In re Paxil, 218 F.R.D. 242 (C.D. Cal. 2003).{{ FIELD }}Defeating efforts to certify a nationwide class of pediatric patients who were prescribed a medication not approved by the FDA to treat patients under 18. Pamela Blain, et al. v. SmithKline Beecham Corp., 240 F.R.D. 179 (E.D. Pa. 2007).{{ FIELD }}Obtaining summary judgments based on federal preemption of state law failure-to-warn claims in cases involving a prescription medication. E.g., O’Neal v. SmithKline Beecham Corp., 551 F.Supp.2d 993 (E.D. Cal. 2008); Candace Miller et al v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline, slip op., 2008 WL 510449 (N.D. Okla).{{ FIELD }}Successfully excluding plaintiff’s experts’ opinions that breast implants cause systemic illness on Daubert grounds in the first breast implant case set for trial in Georgia. Mr. Davis successfully defended that decision on appeal in the first federal appellate decision in the country addressing Daubert issues in the breast implant litigation. Allison v. McGhan Medical Corp. 184 F.3d 1300 (11th Cir. 1999).{{ FIELD }}Successfully defending a product liability lawsuit filed in the “rocket-docket” of the U.S.D.C., Eastern District of Virginia that involved allegations that a uniformed officer of the Secret Service committed murder and then suicide because of a prescription medication. After an intensive 2-1/2 month discovery period, plaintiff dismissed his lawsuit on the eve of trial. The defendant paid nothing in settlement.{{ FIELD }}Successfully defending on appeal summary judgment for a pharmaceutical manufacturer based upon the learned intermediary doctrine. Allgood v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline, No. 06-cv-3506, 2008 WL 483574 (E.D. La. Feb. 20, 2008), aff’d by No. 08- 30329, 2009 WL 646285 (5th Cir. Mar. 13, 2009), reh’g denied by No. 08-30329 (5th Cir. May 6, 2009).{{ FIELD }}Obtaining summary judgment in a product liability lawsuit involving a prescription medication within four months after plaintiff filed his lawsuit, Howard v. GlaxoSmithKline, Case No. 05-1525 (U.S.D.C., E.D. Cal.) aff’d (9th Cir. 2007), and obtaining summary judgments in two product liability wrongful death lawsuits when plaintiffs’ claimed they did not timely file their lawsuit because of the defendant’s “fraudulent concealment.” Pamela Blain, et al., v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline, Civil Action No. 07-1157- MLB-DWB (U.S.D.C., D. Kan.); Collins v. SmithKlineBeecham Corp., Philadelphia Court of Common Pleas, Pennsylvania, aff'd on appeal.{{ FIELD }}Managing massive electronic discovery and hard copy productions and coordinating discovery of plaintiffs’ claims.{{ FIELD }}Successfully defending against motions to compel that sought thousands of privileged documents in personal injury lawsuits involving prescription medications.{{ FIELD }}Major responsibility in several hundred breast implant cases in Georgia, Florida, Alabama, Mississippi, Tennessee, South Carolina, North Carolina, Virginia and the District of Columbia. Mr. Davis second-chaired the trial of the first breast implant case tried in Tennessee. The trial lasted five-and-a-half weeks and included claims of both local and systemic injury. The jury returned a defense verdict.{{ FIELD }}Successfully arguing for transfer of a host of cases to the plaintiffs’ home states under 28 U.S.C. § 1404. (Plaintiffs attempted to bring their lawsuits in the state of the pharmaceutical company’s business office as opposed to the states of their residence.){{ FIELD }}Defending high-ranking company executives in depositions.{{ FIELD }}Representing a manufacturer in an emergency appeal of an order allowing plaintiffs to depose the manufacturer’s in-house litigation counsel. In an appeal to the Kentucky Supreme Court, Mr. Davis successfully argued for reversal of the trial court’s order.{{ FIELD }}Todd Davis is a partner with King \u0026amp; Spalding's Trial \u0026amp; Global Disputes practice group. For the last twenty-eight years, Mr. Davis' practice has been devoted to trying high-stakes products liability cases, including those involving medications, medical devices and consumer products.  His involvement includes cross-examining plaintiffs’ key causation and medical expert witnesses at trial and in deposition.  Mr. Davis’ practice involves representing pharmaceutical and medical device companies, as well as other product manufacturers, in mass tort, consumer fraud and class action litigation.\nMr. Davis has been recognized in Legal 500’s Product Liability and Mass Tort Defense in the Pharma and Medical Device category. Todd P Davis Partner Stetson University Stetson University College of Law Mercer University Mercer University Walter F. George School of Law U.S. Court of Appeals for the Fifth Circuit U.S. Court of Appeals for the Sixth Circuit U.S. Court of Appeals for the Ninth Circuit U.S. Court of Appeals for the Tenth Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. District Court for the Middle District of Florida U.S. District Court for the Middle District of Georgia U.S. District Court for the Northern District of Georgia U.S. District Court for the Southern District of Georgia Florida Georgia American Bar Association State Bar of Georgia Atlanta Bar Association The Florida Bar Sixth and Eleventh Circuit Court of Appeals Trying three cases for GlaxoSmithKline in the Philadelphia Court of Common Pleas, Pennsylvania, alleging that Paxil causes birth defects (2016, 2010, 2009). In two trials, the courts dismissed plaintiffs' claims because plaintiffs could not prove proximate causation. In the third, which was plaintiffs' No. 1 pick for trial, plaintiffs were awarded compensatory damages less than the actual medical expenses incurred and no punitive damages. Trying the first “innovator liability” prescription drug case to go to trial (Dolin v. GSK, 2017). Trying cases for R.J. Reynolds Tobacco Company as part of the Engle-progeny litigation in Florida (2013, 2014, 2018, 2019 and 2020). Representing medical device and pharmaceutical companies in federal multi-district litigation and state consolidated proceedings. Defeating efforts to certify a nationwide class of Paxil users under personal injury and consumer fraud theories. In re Paxil, 212 F.R.D. 539 (C.D. Cal. 2003). This decision has been referred to as one of the “Big Four” federal court rulings denying class certification in pharmaceutical cases. See In re Prempro Prods. Liab. Lit., 230 F.R.D. 555 (E.D. Ark. 2005). Defeating efforts to certify a statewide claim of Paxil users under California’s Unfair Competition Law, § 17200. In re Paxil, 218 F.R.D. 242 (C.D. Cal. 2003). Defeating efforts to certify a nationwide class of pediatric patients who were prescribed a medication not approved by the FDA to treat patients under 18. Pamela Blain, et al. v. SmithKline Beecham Corp., 240 F.R.D. 179 (E.D. Pa. 2007). Obtaining summary judgments based on federal preemption of state law failure-to-warn claims in cases involving a prescription medication. E.g., O’Neal v. SmithKline Beecham Corp., 551 F.Supp.2d 993 (E.D. Cal. 2008); Candace Miller et al v. SmithKline Beecham Corporation, d/b/a GlaxoSmithKline, slip op., 2008 WL 510449 (N.D. Okla). Successfully excluding plaintiff’s experts’ opinions that breast implants cause systemic illness on Daubert grounds in the first breast implant case set for trial in Georgia. Mr. Davis successfully defended that decision on appeal in the first federal appellate decision in the country addressing Daubert issues in the breast implant litigation. Allison v. McGhan Medical Corp. 184 F.3d 1300 (11th Cir. 1999). Successfully defending a product liability lawsuit filed in the “rocket-docket” of the U.S.D.C., Eastern District of Virginia that involved allegations that a uniformed officer of the Secret Service committed murder and then suicide because of a prescription medication. After an intensive 2-1/2 month discovery period, plaintiff dismissed his lawsuit on the eve of trial. The defendant paid nothing in settlement. Successfully defending on appeal summary judgment for a pharmaceutical manufacturer based upon the learned intermediary doctrine. Allgood v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline, No. 06-cv-3506, 2008 WL 483574 (E.D. La. Feb. 20, 2008), aff’d by No. 08- 30329, 2009 WL 646285 (5th Cir. Mar. 13, 2009), reh’g denied by No. 08-30329 (5th Cir. May 6, 2009). Obtaining summary judgment in a product liability lawsuit involving a prescription medication within four months after plaintiff filed his lawsuit, Howard v. GlaxoSmithKline, Case No. 05-1525 (U.S.D.C., E.D. Cal.) aff’d (9th Cir. 2007), and obtaining summary judgments in two product liability wrongful death lawsuits when plaintiffs’ claimed they did not timely file their lawsuit because of the defendant’s “fraudulent concealment.” Pamela Blain, et al., v. SmithKline Beecham Corporation d/b/a GlaxoSmithKline, Civil Action No. 07-1157- MLB-DWB (U.S.D.C., D. Kan.); Collins v. SmithKlineBeecham Corp., Philadelphia Court of Common Pleas, Pennsylvania, aff'd on appeal. Managing massive electronic discovery and hard copy productions and coordinating discovery of plaintiffs’ claims. Successfully defending against motions to compel that sought thousands of privileged documents in personal injury lawsuits involving prescription medications. Major responsibility in several hundred breast implant cases in Georgia, Florida, Alabama, Mississippi, Tennessee, South Carolina, North Carolina, Virginia and the District of Columbia. Mr. Davis second-chaired the trial of the first breast implant case tried in Tennessee. The trial lasted five-and-a-half weeks and included claims of both local and systemic injury. The jury returned a defense verdict. Successfully arguing for transfer of a host of cases to the plaintiffs’ home states under 28 U.S.C. § 1404. (Plaintiffs attempted to bring their lawsuits in the state of the pharmaceutical company’s business office as opposed to the states of their residence.) Defending high-ranking company executives in depositions. Representing a manufacturer in an emergency appeal of an order allowing plaintiffs to depose the manufacturer’s in-house litigation counsel. In an appeal to the Kentucky Supreme Court, Mr. Davis successfully argued for reversal of the trial court’s order.","searchable_name":"Todd P. Davis","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":444001,"version":1,"owner_type":"Person","owner_id":7205,"payload":{"bio":"\u003cp\u003eRob DeConti is a partner in King \u0026amp; Spalding\u0026rsquo;s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG\u0026rsquo;s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government\u0026rsquo;s enforcement and compliance priorities.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government\u0026rsquo;s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG\u0026rsquo;s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government\u0026rsquo;s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG\u0026rsquo;s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\u003c/p\u003e\n\u003cp\u003eBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG\u0026rsquo;s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG\u0026rsquo;s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\u003c/p\u003e\n\u003cp\u003eIn 2007, Rob served as a Special Trial Attorney in DOJ\u0026rsquo;s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel\u0026rsquo;s office at a managed care organization.\u003c/p\u003e","slug":"robert-deconti","email":"rdeconti@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":1,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":2,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"DeConti","nick_name":"Rob","clerkships":[],"first_name":"Robert","title_rank":9999,"updated_by":202,"law_schools":[{"id":3042,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"1999-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"K.","name_suffix":"","recognitions":[{"title":"HHS Secretary’s Award for Distinguished Service","detail":""},{"title":"HHS Secretary’s Award for Meritorious Service","detail":""},{"title":"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)","detail":""},{"title":"Inspector General’s Award for Fighting Fraud, Waste, and Abuse","detail":""},{"title":"President’s Council on Integrity and Efficiency Award for Excellence","detail":""},{"title":"Office of Inspector General Cooperative Achievement Award (multiple awards)","detail":""},{"title":"Inspector General’s Exceptional Achievement Award (multiple awards)","detail":""}],"linked_in_url":"https://www.linkedin.com/in/robertdeconti","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eRob DeConti is a partner in King \u0026amp; Spalding\u0026rsquo;s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG\u0026rsquo;s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government\u0026rsquo;s enforcement and compliance priorities.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government\u0026rsquo;s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG\u0026rsquo;s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government\u0026rsquo;s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG\u0026rsquo;s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\u003c/p\u003e\n\u003cp\u003eBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG\u0026rsquo;s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG\u0026rsquo;s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\u003c/p\u003e\n\u003cp\u003eIn 2007, Rob served as a Special Trial Attorney in DOJ\u0026rsquo;s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel\u0026rsquo;s office at a managed care organization.\u003c/p\u003e","recognitions":[{"title":"HHS Secretary’s Award for Distinguished Service","detail":""},{"title":"HHS Secretary’s Award for Meritorious Service","detail":""},{"title":"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)","detail":""},{"title":"Inspector General’s Award for Fighting Fraud, Waste, and Abuse","detail":""},{"title":"President’s Council on Integrity and Efficiency Award for Excellence","detail":""},{"title":"Office of Inspector General Cooperative Achievement Award (multiple awards)","detail":""},{"title":"Inspector General’s Exceptional Achievement Award (multiple awards)","detail":""}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12841}]},"capability_group_id":2},"created_at":"2025-12-05T05:02:32.000Z","updated_at":"2025-12-05T05:02:32.000Z","searchable_text":"DeConti{{ FIELD }}{:title=\u0026gt;\"HHS Secretary’s Award for Distinguished Service\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"HHS Secretary’s Award for Meritorious Service\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Award for Fighting Fraud, Waste, and Abuse\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"President’s Council on Integrity and Efficiency Award for Excellence\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Office of Inspector General Cooperative Achievement Award (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}{:title=\u0026gt;\"Inspector General’s Exceptional Achievement Award (multiple awards)\", :detail=\u0026gt;\"\"}{{ FIELD }}Rob DeConti is a partner in King \u0026amp; Spalding’s healthcare practice, specializing in government healthcare fraud investigations, compliance, diligence, the False Claims Act, the Anti-Kickback Statute (AKS), and regulatory compliance and enforcement issues in relation to healthcare transactions. Rob is an expert on all aspects of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) administrative remedies and initiatives, including mandatory and permissive exclusion authorities, the Civil Monetary Penalties Law, the Emergency Medical Treatment and Labor Act (EMTALA), corporate integrity agreements, Select Agent investigations, drug price reporting cases, and HHS OIG’s health care, grant, and contractor self-disclosure protocols. Rob has been a frequent presenter for many years at major national healthcare and life sciences conferences, conveying the government’s enforcement and compliance priorities. \nWith over 25 years of experience, including as the former Chief Counsel to HHS OIG, Rob advises healthcare and life sciences companies on complex regulatory and compliance issues. As the highest-ranking attorney for OIG, Rob served as a nationwide expert on the federal government’s development and implementation of health care compliance strategies for health care entities and compliance oversight by health care boards of directors. Rob oversaw all OIG legal services related to audits, investigations, fraud enforcement, and industry guidance. From early in his career as a line attorney with primary responsibility for OIG’s pneumonia upcoding national project, Rob has been significantly involved in many of the federal government’s major healthcare fraud and compliance initiatives over the past 25 years. As Chief Counsel, Rob served as the lead Deputy Inspector General for OIG’s updated compliance program guidance documents, setting forth best practices for entities that do business with the Federal health care programs, including Medicare and Medicaid.\nBefore his role as Chief Counsel, he served for more than a decade as an Assistant Inspector General (AIG) for Legal Affairs. In that position, he was the signatory for OIG advisory opinions on the application of OIG's fraud and abuse authorities, including under the AKS, to the requesting party's existing or proposed business arrangements. He was also responsible for leading OIG’s legal work related to waivers of certain fraud and abuse laws for purposes of testing new health care payment and service delivery models developed by CMS. He has led OIG’s negotiation of Corporate Integrity Agreements (CIAs), with a wide range of providers from across the health care industry. From 2012 to 2016, he served as the OIG signatory on behalf of HHS for all False Claims Act (including qui tam) settlements and CIAs nationwide. \nPrior to becoming AIG in 2012, Rob was the Chief of the Administrative and Civil Remedies Branch, the largest of three branches in the Office of Counsel.\nIn 2007, Rob served as a Special Trial Attorney in DOJ’s Fraud Section, Criminal Division, where he prosecuted matters in connection with phase one of the Medicare Fraud Strike Force in the Southern District of Florida. In that role, Rob was co-counsel for the jury trial leading to conviction on all five criminal counts, including soliciting and receiving kickbacks, of a durable medical equipment company owner who conspired with two Miami pharmacies in a scheme to bill Medicare for expensive inhalation medications. Prior to working at OIG, he worked in the general counsel’s office at a managed care organization. Partner HHS Secretary’s Award for Distinguished Service  HHS Secretary’s Award for Meritorious Service  Inspector General’s Bronze Medal for Outstanding Employee of the Year (multiple awards)  Inspector General’s Award for Fighting Fraud, Waste, and Abuse  President’s Council on Integrity and Efficiency Award for Excellence  Office of Inspector General Cooperative Achievement Award (multiple awards)  Inspector General’s Exceptional Achievement Award (multiple awards)  University of Virginia  American University Washington College of Law American University Washington College of Law District of Columbia Virginia Virginia State Bar American Health Law Association Government Attorney-at-Large, American Bar Association Health Law Section Council, 2022-2025 Government Liaison to the Health Care Compliance Association, Board of Directors, 2008-2012","searchable_name":"Robert K. DeConti (Rob)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":445683,"version":1,"owner_type":"Person","owner_id":7313,"payload":{"bio":"\u003cp\u003eAs a seasoned first-chair trial lawyer and former federal prosecutor, Tinos Diamantatos is a Fellow of the American College of Trial Lawyers, one of the premier, invitation-only legal associations in North America. He is ranked in \u003cem\u003eChambers USA\u003c/em\u003e and noted as \u0026ldquo;an outstanding trial lawyer\u0026rdquo; who is \u0026ldquo;a creative, forceful and tireless advocate\u0026rdquo; and \u0026ldquo;tremendous for clients and a good counselor.\u0026rdquo; He is listed in 2026 \u003cem\u003eLawdragon\u003c/em\u003e 500 Leading Litigators in America, is listed in \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e for White-Collar Criminal Defense, and is recognized and recommended for dispute resolution, corporate investigations, and white-collar defense by the \u003cem\u003eLegal 500\u003c/em\u003e \u003cem\u003eUS\u003c/em\u003e.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eTinos is a premier courtroom advocate and trusted strategic advisor to corporations, boards, C-suites, senior executives, and individuals in their most consequential criminal, regulatory, and complex business litigation. This includes general litigation matters related to government investigations, \u003cem\u003equi tam\u003c/em\u003e litigation, government and internal investigations, and securities enforcement proceedings. He is recognized for leading high-stakes white-collar government enforcement, and complex commercial matters where the margin for error is zero and the cost of failure is existential.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eListed as one of \u003cem\u003eCrain\u0026rsquo;s Chicago Business\u003c/em\u003e \u0026ldquo;Notable Litigators and Trial Attorneys\u0026rdquo; for 2023, Tinos has tried more than 20 cases and achieved an outstanding record of success at trial. Tinos\u0026rsquo; trial representations span jurisdictions in both federal and state courts throughout the United States and have involved complex civil and criminal matters. Included among his trial successes are two separate trial wins for a Fortune 10 company.\u003c/p\u003e\n\u003cp\u003eTinos\u0026rsquo; representations span several industry sectors, including the retail, pharmaceutical, healthcare, pharmacy, medical device, and financial services industries. He has handled investigations, the defense, and prosecutions of matters involving alleged healthcare fraud, commodities fraud, mortgage fraud, money laundering, bank fraud, wire fraud, mail fraud, and tax evasion. He has also handled other complex matters involving terrorism, racketeering, extortion, corruption, obstruction, and civil rights violations.\u003c/p\u003e\n\u003cp\u003eTinos has been trusted by Fortune 500 companies, industry-leading pharmaceutical and healthcare companies, retail pharmacy chains, financial institutions, privately held businesses, and individuals in matters of utmost importance. He helps clients navigate government investigations, regulatory minefields, and related white collar litigation throughout the United States and around the world.\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Tinos was a partner at an AmLaw 25 firm where he served as the Chicago office managing partner and as co-head of that firm\u0026rsquo;s global white collar and government investigations practice group. Before joining private practice, Tinos served as a federal prosecutor at the U.S. Attorney\u0026rsquo;s Office in Chicago where he successfully handled high-profile cases and trials that received national and international media attention. He also successfully served as lead appellate counsel representing the government on nine appeals before the U.S. Court of Appeals for the Second and Seventh Circuits. He served in a number of sections within the Chicago U.S. Attorney\u0026rsquo;s Office, including the Financial Crimes and Special Prosecutions Section, and the office\u0026rsquo;s Public Corruption and Organized Crime Section, where he completed his career as a prosecutor.\u003c/p\u003e\n\u003cp\u003eTinos is also a former federal judicial law clerk and a former president of the prestigious Chicago Inn of Court.\u0026nbsp;He maintains an active pro bono practice and is involved in multiple mentoring initiatives.\u0026nbsp;He is a former member of the John Marshall Law School Board of Trustees and has served as an adjunct trial advocacy professor for the law school, where he has coached many successful trial teams competing at the national level. He teaches, by invitation, law enforcement courses on trial techniques and investigative tactics to federal agents at their national training centers.\u0026nbsp;In 2025, the Hellenic Bar Association recognized him with its \u0026ldquo;Lawyer of the Year\u0026rdquo; Award.\u003c/p\u003e","slug":"tinos-diamantatos","email":"tdiamantatos@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003eCommercial Litigation\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eDefending a major financial institution in a class action involving allegations related to purported violations of state statutes.\u003c/p\u003e","\u003cp\u003eDefending a publicly traded corporation in the managed services industry against allegations of contract fraud.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eFalse Claims Act/Qui Tam Litigation\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eDefending pharmaceutical companies in federal district court and state court in an action brought by a government entity alleging improper marketing of opioids. Recently successfully obtained dismissal of action.\u003c/p\u003e","\u003cp\u003eDefending ongoing FCA litigation for a national healthcare provider in federal district court following Department of Justice intervention on allegations related to improper physician billing.\u003c/p\u003e","\u003cp\u003eDefended pharmaceutical companies in multiple government investigations involving allegations related to off-label promotion and marketing practices.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eCriminal Investigations\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eRepresenting a large financial institution in connection with a Department of Justice inquiry.\u003c/p\u003e","\u003cp\u003eRepresenting multiple individual physicians in connection with various federal investigations of alleged healthcare fraud and improper billing practices.\u003c/p\u003e","\u003cp\u003eRepresenting an individual in a Department of Justice investigation into allegations of fraud and corruption.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eSecurities Fraud\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eRepresenting a medical device manufacturer in connection with a Securities and Exchange Commission enforcement proceeding.\u003c/p\u003e","\u003cp\u003eRepresented individual under investigation for alleged insider trading. Matter recently closed by the Securities and Exchange Commission with no adverse action taken.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eInternal Investigations\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eConducted an internal investigation for multi-national corporation stemming from alleged violations of money laundering, structuring, and related financial reporting requirements.\u003c/p\u003e","\u003cp\u003eConducted a variety of internal investigations of potential abuse and procurement fraud.\u003c/p\u003e","\u003cp\u003eCounseled clients on FCPA issues and compliance programs.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":74,"guid":"74.capabilities","index":0,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":1,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":2,"source":"capabilities"},{"id":19,"guid":"19.capabilities","index":3,"source":"capabilities"},{"id":27,"guid":"27.capabilities","index":4,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":5,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":6,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":7,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":8,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":9,"source":"capabilities"},{"id":1142,"guid":"1142.smart_tags","index":10,"source":"smartTags"},{"id":764,"guid":"764.smart_tags","index":11,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":12,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":13,"source":"smartTags"},{"id":1248,"guid":"1248.smart_tags","index":14,"source":"smartTags"},{"id":1715,"guid":"1715.smart_tags","index":15,"source":"smartTags"},{"id":750,"guid":"750.smart_tags","index":16,"source":"smartTags"},{"id":762,"guid":"762.smart_tags","index":17,"source":"smartTags"}],"is_active":true,"last_name":"Diamantatos","nick_name":"Tinos","clerkships":[{"name":"Law Clerk, Judge Charles P. Kocoras, Northern District of Illinois","years_held":"2004 - 2005"}],"first_name":"Tinos","title_rank":9999,"updated_by":176,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Fellow","detail":"American College of Trial Lawyers"},{"title":"500 Leading Litigators in America","detail":"Lawdragon, 2026"},{"title":"Illinois Lawyer of the Year","detail":"Hellenic Bar Association, 2025"},{"title":"Notable Litigators and Trial Attorneys","detail":"Crain’s Chicago Business (2023)"},{"title":"Recognized for Criminal Defense: White-Collar, Chicago","detail":"The Best Lawyers in America, (2023–2025)"},{"title":"Litigation: White-Collar Crime \u0026 Government Investigations – Illinois","detail":"Chambers USA (2021–2025)"},{"title":"Up and Coming, Litigation: White-Collar Crime \u0026 Government Investigations – Illinois","detail":"Chambers USA (2020)"},{"title":"Dispute resolution: Corporate investigations and white-collar criminal defense","detail":"The Legal 500 US (2016, 2018–2025)"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAs a seasoned first-chair trial lawyer and former federal prosecutor, Tinos Diamantatos is a Fellow of the American College of Trial Lawyers, one of the premier, invitation-only legal associations in North America. He is ranked in \u003cem\u003eChambers USA\u003c/em\u003e and noted as \u0026ldquo;an outstanding trial lawyer\u0026rdquo; who is \u0026ldquo;a creative, forceful and tireless advocate\u0026rdquo; and \u0026ldquo;tremendous for clients and a good counselor.\u0026rdquo; He is listed in 2026 \u003cem\u003eLawdragon\u003c/em\u003e 500 Leading Litigators in America, is listed in \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e for White-Collar Criminal Defense, and is recognized and recommended for dispute resolution, corporate investigations, and white-collar defense by the \u003cem\u003eLegal 500\u003c/em\u003e \u003cem\u003eUS\u003c/em\u003e.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eTinos is a premier courtroom advocate and trusted strategic advisor to corporations, boards, C-suites, senior executives, and individuals in their most consequential criminal, regulatory, and complex business litigation. This includes general litigation matters related to government investigations, \u003cem\u003equi tam\u003c/em\u003e litigation, government and internal investigations, and securities enforcement proceedings. He is recognized for leading high-stakes white-collar government enforcement, and complex commercial matters where the margin for error is zero and the cost of failure is existential.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eListed as one of \u003cem\u003eCrain\u0026rsquo;s Chicago Business\u003c/em\u003e \u0026ldquo;Notable Litigators and Trial Attorneys\u0026rdquo; for 2023, Tinos has tried more than 20 cases and achieved an outstanding record of success at trial. Tinos\u0026rsquo; trial representations span jurisdictions in both federal and state courts throughout the United States and have involved complex civil and criminal matters. Included among his trial successes are two separate trial wins for a Fortune 10 company.\u003c/p\u003e\n\u003cp\u003eTinos\u0026rsquo; representations span several industry sectors, including the retail, pharmaceutical, healthcare, pharmacy, medical device, and financial services industries. He has handled investigations, the defense, and prosecutions of matters involving alleged healthcare fraud, commodities fraud, mortgage fraud, money laundering, bank fraud, wire fraud, mail fraud, and tax evasion. He has also handled other complex matters involving terrorism, racketeering, extortion, corruption, obstruction, and civil rights violations.\u003c/p\u003e\n\u003cp\u003eTinos has been trusted by Fortune 500 companies, industry-leading pharmaceutical and healthcare companies, retail pharmacy chains, financial institutions, privately held businesses, and individuals in matters of utmost importance. He helps clients navigate government investigations, regulatory minefields, and related white collar litigation throughout the United States and around the world.\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Tinos was a partner at an AmLaw 25 firm where he served as the Chicago office managing partner and as co-head of that firm\u0026rsquo;s global white collar and government investigations practice group. Before joining private practice, Tinos served as a federal prosecutor at the U.S. Attorney\u0026rsquo;s Office in Chicago where he successfully handled high-profile cases and trials that received national and international media attention. He also successfully served as lead appellate counsel representing the government on nine appeals before the U.S. Court of Appeals for the Second and Seventh Circuits. He served in a number of sections within the Chicago U.S. Attorney\u0026rsquo;s Office, including the Financial Crimes and Special Prosecutions Section, and the office\u0026rsquo;s Public Corruption and Organized Crime Section, where he completed his career as a prosecutor.\u003c/p\u003e\n\u003cp\u003eTinos is also a former federal judicial law clerk and a former president of the prestigious Chicago Inn of Court.\u0026nbsp;He maintains an active pro bono practice and is involved in multiple mentoring initiatives.\u0026nbsp;He is a former member of the John Marshall Law School Board of Trustees and has served as an adjunct trial advocacy professor for the law school, where he has coached many successful trial teams competing at the national level. He teaches, by invitation, law enforcement courses on trial techniques and investigative tactics to federal agents at their national training centers.\u0026nbsp;In 2025, the Hellenic Bar Association recognized him with its \u0026ldquo;Lawyer of the Year\u0026rdquo; Award.\u003c/p\u003e","matters":["\u003cp\u003e\u003cstrong\u003eCommercial Litigation\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eDefending a major financial institution in a class action involving allegations related to purported violations of state statutes.\u003c/p\u003e","\u003cp\u003eDefending a publicly traded corporation in the managed services industry against allegations of contract fraud.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eFalse Claims Act/Qui Tam Litigation\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eDefending pharmaceutical companies in federal district court and state court in an action brought by a government entity alleging improper marketing of opioids. Recently successfully obtained dismissal of action.\u003c/p\u003e","\u003cp\u003eDefending ongoing FCA litigation for a national healthcare provider in federal district court following Department of Justice intervention on allegations related to improper physician billing.\u003c/p\u003e","\u003cp\u003eDefended pharmaceutical companies in multiple government investigations involving allegations related to off-label promotion and marketing practices.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eCriminal Investigations\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eRepresenting a large financial institution in connection with a Department of Justice inquiry.\u003c/p\u003e","\u003cp\u003eRepresenting multiple individual physicians in connection with various federal investigations of alleged healthcare fraud and improper billing practices.\u003c/p\u003e","\u003cp\u003eRepresenting an individual in a Department of Justice investigation into allegations of fraud and corruption.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eSecurities Fraud\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eRepresenting a medical device manufacturer in connection with a Securities and Exchange Commission enforcement proceeding.\u003c/p\u003e","\u003cp\u003eRepresented individual under investigation for alleged insider trading. Matter recently closed by the Securities and Exchange Commission with no adverse action taken.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eInternal Investigations\u003c/strong\u003e\u003c/p\u003e","\u003cp\u003eConducted an internal investigation for multi-national corporation stemming from alleged violations of money laundering, structuring, and related financial reporting requirements.\u003c/p\u003e","\u003cp\u003eConducted a variety of internal investigations of potential abuse and procurement fraud.\u003c/p\u003e","\u003cp\u003eCounseled clients on FCPA issues and compliance programs.\u003c/p\u003e"],"recognitions":[{"title":"Fellow","detail":"American College of Trial Lawyers"},{"title":"500 Leading Litigators in America","detail":"Lawdragon, 2026"},{"title":"Illinois Lawyer of the Year","detail":"Hellenic Bar Association, 2025"},{"title":"Notable Litigators and Trial Attorneys","detail":"Crain’s Chicago Business (2023)"},{"title":"Recognized for Criminal Defense: White-Collar, Chicago","detail":"The Best Lawyers in America, (2023–2025)"},{"title":"Litigation: White-Collar Crime \u0026 Government Investigations – Illinois","detail":"Chambers USA (2021–2025)"},{"title":"Up and Coming, Litigation: White-Collar Crime \u0026 Government Investigations – Illinois","detail":"Chambers USA (2020)"},{"title":"Dispute resolution: Corporate investigations and white-collar criminal defense","detail":"The Legal 500 US (2016, 2018–2025)"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":13354}]},"capability_group_id":3},"created_at":"2026-02-09T16:03:46.000Z","updated_at":"2026-02-09T16:03:46.000Z","searchable_text":"Diamantatos{{ FIELD }}{:title=\u0026gt;\"Fellow\", :detail=\u0026gt;\"American College of Trial Lawyers\"}{{ FIELD }}{:title=\u0026gt;\"500 Leading Litigators in America\", :detail=\u0026gt;\"Lawdragon, 2026\"}{{ FIELD }}{:title=\u0026gt;\"Illinois Lawyer of the Year\", :detail=\u0026gt;\"Hellenic Bar Association, 2025\"}{{ FIELD }}{:title=\u0026gt;\"Notable Litigators and Trial Attorneys\", :detail=\u0026gt;\"Crain’s Chicago Business (2023)\"}{{ FIELD }}{:title=\u0026gt;\"Recognized for Criminal Defense: White-Collar, Chicago\", :detail=\u0026gt;\"The Best Lawyers in America, (2023–2025)\"}{{ FIELD }}{:title=\u0026gt;\"Litigation: White-Collar Crime \u0026amp; Government Investigations – Illinois\", :detail=\u0026gt;\"Chambers USA (2021–2025)\"}{{ FIELD }}{:title=\u0026gt;\"Up and Coming, Litigation: White-Collar Crime \u0026amp; Government Investigations – Illinois\", :detail=\u0026gt;\"Chambers USA (2020)\"}{{ FIELD }}{:title=\u0026gt;\"Dispute resolution: Corporate investigations and white-collar criminal defense\", :detail=\u0026gt;\"The Legal 500 US (2016, 2018–2025)\"}{{ FIELD }}Commercial Litigation{{ FIELD }}Defending a major financial institution in a class action involving allegations related to purported violations of state statutes.{{ FIELD }}Defending a publicly traded corporation in the managed services industry against allegations of contract fraud.{{ FIELD }}False Claims Act/Qui Tam Litigation{{ FIELD }}Defending pharmaceutical companies in federal district court and state court in an action brought by a government entity alleging improper marketing of opioids. Recently successfully obtained dismissal of action.{{ FIELD }}Defending ongoing FCA litigation for a national healthcare provider in federal district court following Department of Justice intervention on allegations related to improper physician billing.{{ FIELD }}Defended pharmaceutical companies in multiple government investigations involving allegations related to off-label promotion and marketing practices.{{ FIELD }}Criminal Investigations{{ FIELD }}Representing a large financial institution in connection with a Department of Justice inquiry.{{ FIELD }}Representing multiple individual physicians in connection with various federal investigations of alleged healthcare fraud and improper billing practices.{{ FIELD }}Representing an individual in a Department of Justice investigation into allegations of fraud and corruption.{{ FIELD }}Securities Fraud{{ FIELD }}Representing a medical device manufacturer in connection with a Securities and Exchange Commission enforcement proceeding.{{ FIELD }}Represented individual under investigation for alleged insider trading. Matter recently closed by the Securities and Exchange Commission with no adverse action taken.{{ FIELD }}Internal Investigations{{ FIELD }}Conducted an internal investigation for multi-national corporation stemming from alleged violations of money laundering, structuring, and related financial reporting requirements.{{ FIELD }}Conducted a variety of internal investigations of potential abuse and procurement fraud.{{ FIELD }}Counseled clients on FCPA issues and compliance programs.{{ FIELD }}As a seasoned first-chair trial lawyer and former federal prosecutor, Tinos Diamantatos is a Fellow of the American College of Trial Lawyers, one of the premier, invitation-only legal associations in North America. He is ranked in Chambers USA and noted as “an outstanding trial lawyer” who is “a creative, forceful and tireless advocate” and “tremendous for clients and a good counselor.” He is listed in 2026 Lawdragon 500 Leading Litigators in America, is listed in The Best Lawyers in America for White-Collar Criminal Defense, and is recognized and recommended for dispute resolution, corporate investigations, and white-collar defense by the Legal 500 US.\nTinos is a premier courtroom advocate and trusted strategic advisor to corporations, boards, C-suites, senior executives, and individuals in their most consequential criminal, regulatory, and complex business litigation. This includes general litigation matters related to government investigations, qui tam litigation, government and internal investigations, and securities enforcement proceedings. He is recognized for leading high-stakes white-collar government enforcement, and complex commercial matters where the margin for error is zero and the cost of failure is existential. \nListed as one of Crain’s Chicago Business “Notable Litigators and Trial Attorneys” for 2023, Tinos has tried more than 20 cases and achieved an outstanding record of success at trial. Tinos’ trial representations span jurisdictions in both federal and state courts throughout the United States and have involved complex civil and criminal matters. Included among his trial successes are two separate trial wins for a Fortune 10 company.\nTinos’ representations span several industry sectors, including the retail, pharmaceutical, healthcare, pharmacy, medical device, and financial services industries. He has handled investigations, the defense, and prosecutions of matters involving alleged healthcare fraud, commodities fraud, mortgage fraud, money laundering, bank fraud, wire fraud, mail fraud, and tax evasion. He has also handled other complex matters involving terrorism, racketeering, extortion, corruption, obstruction, and civil rights violations.\nTinos has been trusted by Fortune 500 companies, industry-leading pharmaceutical and healthcare companies, retail pharmacy chains, financial institutions, privately held businesses, and individuals in matters of utmost importance. He helps clients navigate government investigations, regulatory minefields, and related white collar litigation throughout the United States and around the world.\nPrior to joining King \u0026amp; Spalding, Tinos was a partner at an AmLaw 25 firm where he served as the Chicago office managing partner and as co-head of that firm’s global white collar and government investigations practice group. Before joining private practice, Tinos served as a federal prosecutor at the U.S. Attorney’s Office in Chicago where he successfully handled high-profile cases and trials that received national and international media attention. He also successfully served as lead appellate counsel representing the government on nine appeals before the U.S. Court of Appeals for the Second and Seventh Circuits. He served in a number of sections within the Chicago U.S. Attorney’s Office, including the Financial Crimes and Special Prosecutions Section, and the office’s Public Corruption and Organized Crime Section, where he completed his career as a prosecutor.\nTinos is also a former federal judicial law clerk and a former president of the prestigious Chicago Inn of Court. He maintains an active pro bono practice and is involved in multiple mentoring initiatives. He is a former member of the John Marshall Law School Board of Trustees and has served as an adjunct trial advocacy professor for the law school, where he has coached many successful trial teams competing at the national level. He teaches, by invitation, law enforcement courses on trial techniques and investigative tactics to federal agents at their national training centers. In 2025, the Hellenic Bar Association recognized him with its “Lawyer of the Year” Award. Partner Fellow American College of Trial Lawyers 500 Leading Litigators in America Lawdragon, 2026 Illinois Lawyer of the Year Hellenic Bar Association, 2025 Notable Litigators and Trial Attorneys Crain’s Chicago Business (2023) Recognized for Criminal Defense: White-Collar, Chicago The Best Lawyers in America, (2023–2025) Litigation: White-Collar Crime \u0026amp; Government Investigations – Illinois Chambers USA (2021–2025) Up and Coming, Litigation: White-Collar Crime \u0026amp; Government Investigations – Illinois Chambers USA (2020) Dispute resolution: Corporate investigations and white-collar criminal defense The Legal 500 US (2016, 2018–2025) DePaul University DePaul University College of Law The John Marshall Law School The John Marshall Law School U.S. Court of Appeals for the Second Circuit U.S. Court of Appeals for the Seventh Circuit Illinois Member, American Bar Association Member, Federal Bar Association Member, Chicago Bar Association President, Chicago Inn of Court (2017–2018) Member, Seventh Circuit Bar Association Member, Hellenic Bar Association Member, The John Marshall Law School Board of Trustees Member, Order of John Marshall Law Clerk, Judge Charles P. Kocoras, Northern District of Illinois Commercial Litigation Defending a major financial institution in a class action involving allegations related to purported violations of state statutes. Defending a publicly traded corporation in the managed services industry against allegations of contract fraud. False Claims Act/Qui Tam Litigation Defending pharmaceutical companies in federal district court and state court in an action brought by a government entity alleging improper marketing of opioids. Recently successfully obtained dismissal of action. Defending ongoing FCA litigation for a national healthcare provider in federal district court following Department of Justice intervention on allegations related to improper physician billing. Defended pharmaceutical companies in multiple government investigations involving allegations related to off-label promotion and marketing practices. Criminal Investigations Representing a large financial institution in connection with a Department of Justice inquiry. Representing multiple individual physicians in connection with various federal investigations of alleged healthcare fraud and improper billing practices. Representing an individual in a Department of Justice investigation into allegations of fraud and corruption. Securities Fraud Representing a medical device manufacturer in connection with a Securities and Exchange Commission enforcement proceeding. Represented individual under investigation for alleged insider trading. Matter recently closed by the Securities and Exchange Commission with no adverse action taken. Internal Investigations Conducted an internal investigation for multi-national corporation stemming from alleged violations of money laundering, structuring, and related financial reporting requirements. Conducted a variety of internal investigations of potential abuse and procurement fraud. Counseled clients on FCPA issues and compliance programs.","searchable_name":"Tinos Diamantatos","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":176,"capability_group_featured":null,"home_page_featured":null},{"id":443116,"version":1,"owner_type":"Person","owner_id":7201,"payload":{"bio":"\u003cp\u003eAkash\u0026nbsp;represents\u0026nbsp;companies in complex litigation and government investigations. He\u0026nbsp;possesses\u0026nbsp;a breadth\u0026nbsp;of litigation and enforcement experience informed by six years of service as both an Assistant United States Attorney in the Northern District of Georgia and Senior Litigation Counsel at the Consumer Financial Protection Bureau\u0026nbsp;handling litigations and investigations\u0026nbsp;in the healthcare and financial sectors. Before his career\u0026nbsp;in government, Akash also spent\u0026nbsp;nearly eight years as a litigator at two global law firms.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAs an Assistant United States Attorney in the Northern District of Georgia, Akash litigated\u0026nbsp;and investigated an array of False Claims Act matters, including those\u0026nbsp;involving kickbacks, medically unnecessary services, and violations of federal cybersecurity requirements. During his tenure, he\u0026nbsp;co-tried a case resulting in\u0026nbsp;a $27 million judgment\u0026nbsp;against a Georgia doctor and his medical practice for violating the False Claims Act.\u003c/p\u003e\n\u003cp\u003eAs a Senior Litigation Counsel at the Consumer Financial Protection Bureau, Akash litigated and investigated violations of consumer financial law. His experience included investigating the data security practices of a large financial services provider that experienced a data breach and\u0026nbsp;litigating a complex action alongside several State Attorney General\u0026nbsp;Offices.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEarlier in private practice, Akash worked on complex commercial, financial, and intellectual property litigation in federal and state venues across the country.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAkash received his J.D. from Vanderbilt University Law School, where he was on the editorial board of the Vanderbilt Journal of Transnational Law and a Moot Court Board member. He\u0026nbsp;also received his LL.M. in International Legal Studies from New York University School of Law and his\u0026nbsp;B.A. in Political Science with honors from the University of Rochester.\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e","slug":"akash-desai","email":"adesai@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":2,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":3,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":1180,"guid":"1180.smart_tags","index":6,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":7,"source":"smartTags"},{"id":740,"guid":"740.smart_tags","index":8,"source":"smartTags"}],"is_active":true,"last_name":"Desai","nick_name":"Akash","clerkships":[{"name":"Law Clerk, Hon. Jon P. McCalla, U.S. District Court for the Western District of Tennessee","years_held":"2004 - 2005"},{"name":"Law Clerk, Hon. Aleta A. Trauger, U.S. District Court for the Middle District of Tennessee","years_held":"2011 - 2013"},{"name":"Law Clerk, Hon. S. Martin Teel, Jr., U.S. Bankruptcy Court for the District of Columbia","years_held":"2011 - 2011"}],"first_name":"Akash","title_rank":9999,"updated_by":202,"law_schools":[{"id":2442,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2004-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null},{"id":1406,"meta":{"degree":"LL.M.","honors":"","is_law_school":"1","graduation_date":"2009-01-01 00:00:00"},"order":2,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":14,"translated_fields":{"en":{"bio":"\u003cp\u003eAkash\u0026nbsp;represents\u0026nbsp;companies in complex litigation and government investigations. He\u0026nbsp;possesses\u0026nbsp;a breadth\u0026nbsp;of litigation and enforcement experience informed by six years of service as both an Assistant United States Attorney in the Northern District of Georgia and Senior Litigation Counsel at the Consumer Financial Protection Bureau\u0026nbsp;handling litigations and investigations\u0026nbsp;in the healthcare and financial sectors. Before his career\u0026nbsp;in government, Akash also spent\u0026nbsp;nearly eight years as a litigator at two global law firms.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAs an Assistant United States Attorney in the Northern District of Georgia, Akash litigated\u0026nbsp;and investigated an array of False Claims Act matters, including those\u0026nbsp;involving kickbacks, medically unnecessary services, and violations of federal cybersecurity requirements. During his tenure, he\u0026nbsp;co-tried a case resulting in\u0026nbsp;a $27 million judgment\u0026nbsp;against a Georgia doctor and his medical practice for violating the False Claims Act.\u003c/p\u003e\n\u003cp\u003eAs a Senior Litigation Counsel at the Consumer Financial Protection Bureau, Akash litigated and investigated violations of consumer financial law. His experience included investigating the data security practices of a large financial services provider that experienced a data breach and\u0026nbsp;litigating a complex action alongside several State Attorney General\u0026nbsp;Offices.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEarlier in private practice, Akash worked on complex commercial, financial, and intellectual property litigation in federal and state venues across the country.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAkash received his J.D. from Vanderbilt University Law School, where he was on the editorial board of the Vanderbilt Journal of Transnational Law and a Moot Court Board member. He\u0026nbsp;also received his LL.M. in International Legal Studies from New York University School of Law and his\u0026nbsp;B.A. in Political Science with honors from the University of Rochester.\u0026nbsp;\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12899}]},"capability_group_id":2},"created_at":"2025-11-19T16:33:25.000Z","updated_at":"2025-11-19T16:33:25.000Z","searchable_text":"Desai{{ FIELD }}Akash represents companies in complex litigation and government investigations. He possesses a breadth of litigation and enforcement experience informed by six years of service as both an Assistant United States Attorney in the Northern District of Georgia and Senior Litigation Counsel at the Consumer Financial Protection Bureau handling litigations and investigations in the healthcare and financial sectors. Before his career in government, Akash also spent nearly eight years as a litigator at two global law firms. \nAs an Assistant United States Attorney in the Northern District of Georgia, Akash litigated and investigated an array of False Claims Act matters, including those involving kickbacks, medically unnecessary services, and violations of federal cybersecurity requirements. During his tenure, he co-tried a case resulting in a $27 million judgment against a Georgia doctor and his medical practice for violating the False Claims Act.\nAs a Senior Litigation Counsel at the Consumer Financial Protection Bureau, Akash litigated and investigated violations of consumer financial law. His experience included investigating the data security practices of a large financial services provider that experienced a data breach and litigating a complex action alongside several State Attorney General Offices. \nEarlier in private practice, Akash worked on complex commercial, financial, and intellectual property litigation in federal and state venues across the country. \nAkash received his J.D. from Vanderbilt University Law School, where he was on the editorial board of the Vanderbilt Journal of Transnational Law and a Moot Court Board member. He also received his LL.M. in International Legal Studies from New York University School of Law and his B.A. in Political Science with honors from the University of Rochester.     Counsel University of Rochester  Vanderbilt University Vanderbilt University School of Law New York University New York University School of Law Georgia New York Law Clerk, Hon. Jon P. McCalla, U.S. District Court for the Western District of Tennessee Law Clerk, Hon. Aleta A. Trauger, U.S. District Court for the Middle District of Tennessee Law Clerk, Hon. S. Martin Teel, Jr., U.S. Bankruptcy Court for the District of Columbia","searchable_name":"Akash Desai","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426723,"version":1,"owner_type":"Person","owner_id":5435,"payload":{"bio":"\u003cp\u003eAlex is an Associate in our Special Matters and Government Investigations practice and is licensed to practice in Texas and England and Wales. Alex represents clients involved in complex, multi-jurisdictional disputes and government investigations. Alex has experience representing corporations and individuals in matters involving a wide range of criminal and regulatory misconduct including cybersecurity, financial crime, bribery and corruption, and violations of environmental and healthcare laws and regulations. The majority of Alex\u0026rsquo;s experience involves more than one jurisdiction.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Alex began practicing as a barrister in London, United Kingdom, where he gained experience prosecuting and defending.\u0026nbsp;Alex built upon his trial experience by joining a large international U.S. firm in London, where Alex defended corporations and individuals facing complex global criminal and regulatory investigations and disputes.\u003c/p\u003e\n\u003cp\u003eSince joining King \u0026amp; Spalding in 2018, Alex\u0026rsquo;s practice has evolved to focus on cybercrime to complement his experience representing clients in investigations and prosecutions alleging corruption, anti-trust offences, fraud, money laundering, false accounting and other allegations of criminal and regulatory misconduct. Alex has experience in matters involving extradition and mutual legal assistance, proceeds of crime and international sanctions.\u003c/p\u003e\n\u003cp\u003eMost recently, Alex\u0026rsquo;s cybersecurity investigations work has involved: investigating cybersecurity breaches and the associated incident response; attribution of systematic and targeted compromise of an opposing party\u0026rsquo;s email servers, responding to allegations related to a technically complex and vast multi-jurisdictional compromise of mobile devices; investigating and identifying potential weaknesses in malware which utilizes unique attributes to resist common take down measures. Alex also advises clients seeking to invest in critical infrastructure assets of importance to United States\u0026rsquo; national security.\u003c/p\u003e\n\u003cp\u003eAlex\u0026rsquo;s experience practicing in two of the most active enforcement jurisdictions - the United States and the United Kingdom - benefits clients facing investigations in multiple jurisdictions.\u003c/p\u003e\n\u003cp\u003eIn addition to investigations work, Alex has designed, implemented and tested compliance processes and advised on pre/post-acquisition due diligence in the areas covered by his investigations practice.\u003c/p\u003e\n\u003cp\u003eAlex has represented clients in interviews with government authorities (both as suspects and as witnesses) and has conducted interviews on behalf of corporations when conducting internal investigations.\u003c/p\u003e\n\u003cp\u003eAlex is experienced in all aspects of the investigation process, both internal investigation and investigations conducted by enforcement authorities. Alex\u0026rsquo;s comfort with new and emerging technology ensures he is on top of the various challenges posed by a corporation's use of technology and electronic data. Alex has conducted internal investigations on a wide range of matters, including those related to cyber-crimes, bribery and corruption, and fraud allegations related to healthcare, accounting, emissions, bankruptcy, tax, and real estate, among other areas.\u003c/p\u003e\n\u003cp\u003eAlex represents clients across various industries including technology, energy, automotive, financial services, healthcare, construction, retail and food and beverage industries.\u003c/p\u003e","slug":"alexander-davey","email":"adavey@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":11,"guid":"11.capabilities","index":0,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":780,"guid":"780.smart_tags","index":3,"source":"smartTags"},{"id":20,"guid":"20.capabilities","index":4,"source":"capabilities"},{"id":766,"guid":"766.smart_tags","index":5,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":6,"source":"smartTags"},{"id":1197,"guid":"1197.smart_tags","index":7,"source":"smartTags"},{"id":106,"guid":"106.capabilities","index":8,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":9,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":10,"source":"capabilities"}],"is_active":true,"last_name":"Davey","nick_name":"Alex","clerkships":[],"first_name":"Alexander","title_rank":9999,"updated_by":34,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":75,"translated_fields":{"en":{"bio":"\u003cp\u003eAlex is an Associate in our Special Matters and Government Investigations practice and is licensed to practice in Texas and England and Wales. Alex represents clients involved in complex, multi-jurisdictional disputes and government investigations. Alex has experience representing corporations and individuals in matters involving a wide range of criminal and regulatory misconduct including cybersecurity, financial crime, bribery and corruption, and violations of environmental and healthcare laws and regulations. The majority of Alex\u0026rsquo;s experience involves more than one jurisdiction.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Alex began practicing as a barrister in London, United Kingdom, where he gained experience prosecuting and defending.\u0026nbsp;Alex built upon his trial experience by joining a large international U.S. firm in London, where Alex defended corporations and individuals facing complex global criminal and regulatory investigations and disputes.\u003c/p\u003e\n\u003cp\u003eSince joining King \u0026amp; Spalding in 2018, Alex\u0026rsquo;s practice has evolved to focus on cybercrime to complement his experience representing clients in investigations and prosecutions alleging corruption, anti-trust offences, fraud, money laundering, false accounting and other allegations of criminal and regulatory misconduct. Alex has experience in matters involving extradition and mutual legal assistance, proceeds of crime and international sanctions.\u003c/p\u003e\n\u003cp\u003eMost recently, Alex\u0026rsquo;s cybersecurity investigations work has involved: investigating cybersecurity breaches and the associated incident response; attribution of systematic and targeted compromise of an opposing party\u0026rsquo;s email servers, responding to allegations related to a technically complex and vast multi-jurisdictional compromise of mobile devices; investigating and identifying potential weaknesses in malware which utilizes unique attributes to resist common take down measures. Alex also advises clients seeking to invest in critical infrastructure assets of importance to United States\u0026rsquo; national security.\u003c/p\u003e\n\u003cp\u003eAlex\u0026rsquo;s experience practicing in two of the most active enforcement jurisdictions - the United States and the United Kingdom - benefits clients facing investigations in multiple jurisdictions.\u003c/p\u003e\n\u003cp\u003eIn addition to investigations work, Alex has designed, implemented and tested compliance processes and advised on pre/post-acquisition due diligence in the areas covered by his investigations practice.\u003c/p\u003e\n\u003cp\u003eAlex has represented clients in interviews with government authorities (both as suspects and as witnesses) and has conducted interviews on behalf of corporations when conducting internal investigations.\u003c/p\u003e\n\u003cp\u003eAlex is experienced in all aspects of the investigation process, both internal investigation and investigations conducted by enforcement authorities. Alex\u0026rsquo;s comfort with new and emerging technology ensures he is on top of the various challenges posed by a corporation's use of technology and electronic data. Alex has conducted internal investigations on a wide range of matters, including those related to cyber-crimes, bribery and corruption, and fraud allegations related to healthcare, accounting, emissions, bankruptcy, tax, and real estate, among other areas.\u003c/p\u003e\n\u003cp\u003eAlex represents clients across various industries including technology, energy, automotive, financial services, healthcare, construction, retail and food and beverage industries.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":6586}]},"capability_group_id":2},"created_at":"2025-05-26T04:56:21.000Z","updated_at":"2025-05-26T04:56:21.000Z","searchable_text":"Davey{{ FIELD }}Alex is an Associate in our Special Matters and Government Investigations practice and is licensed to practice in Texas and England and Wales. Alex represents clients involved in complex, multi-jurisdictional disputes and government investigations. Alex has experience representing corporations and individuals in matters involving a wide range of criminal and regulatory misconduct including cybersecurity, financial crime, bribery and corruption, and violations of environmental and healthcare laws and regulations. The majority of Alex’s experience involves more than one jurisdiction.\nPrior to joining King \u0026amp; Spalding, Alex began practicing as a barrister in London, United Kingdom, where he gained experience prosecuting and defending. Alex built upon his trial experience by joining a large international U.S. firm in London, where Alex defended corporations and individuals facing complex global criminal and regulatory investigations and disputes.\nSince joining King \u0026amp; Spalding in 2018, Alex’s practice has evolved to focus on cybercrime to complement his experience representing clients in investigations and prosecutions alleging corruption, anti-trust offences, fraud, money laundering, false accounting and other allegations of criminal and regulatory misconduct. Alex has experience in matters involving extradition and mutual legal assistance, proceeds of crime and international sanctions.\nMost recently, Alex’s cybersecurity investigations work has involved: investigating cybersecurity breaches and the associated incident response; attribution of systematic and targeted compromise of an opposing party’s email servers, responding to allegations related to a technically complex and vast multi-jurisdictional compromise of mobile devices; investigating and identifying potential weaknesses in malware which utilizes unique attributes to resist common take down measures. Alex also advises clients seeking to invest in critical infrastructure assets of importance to United States’ national security.\nAlex’s experience practicing in two of the most active enforcement jurisdictions - the United States and the United Kingdom - benefits clients facing investigations in multiple jurisdictions.\nIn addition to investigations work, Alex has designed, implemented and tested compliance processes and advised on pre/post-acquisition due diligence in the areas covered by his investigations practice.\nAlex has represented clients in interviews with government authorities (both as suspects and as witnesses) and has conducted interviews on behalf of corporations when conducting internal investigations.\nAlex is experienced in all aspects of the investigation process, both internal investigation and investigations conducted by enforcement authorities. Alex’s comfort with new and emerging technology ensures he is on top of the various challenges posed by a corporation's use of technology and electronic data. Alex has conducted internal investigations on a wide range of matters, including those related to cyber-crimes, bribery and corruption, and fraud allegations related to healthcare, accounting, emissions, bankruptcy, tax, and real estate, among other areas.\nAlex represents clients across various industries including technology, energy, automotive, financial services, healthcare, construction, retail and food and beverage industries. Senior Associate University of East Anglia University of East Anglia University of Law, London University of Law, London Texas England and Wales","searchable_name":"Alexander Davey (Alex)","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":34,"capability_group_featured":null,"home_page_featured":null},{"id":445744,"version":1,"owner_type":"Person","owner_id":6779,"payload":{"bio":"\u003cp\u003eTyler Dysart is an associate in the firm\u0026rsquo;s Healthcare practice group. Tyler represents hospitals and other clients\u0026nbsp;in the healthcare and life sciences industries involved in complex litigation, arbitration, government investigations, and transactions.\u0026nbsp; Tyler routinely advises on the complex regulatory, contractual, and other commercial issues affecting these entities.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eTyler graduated\u0026nbsp;\u003cem\u003ecum laude\u003c/em\u003e\u0026nbsp;from the University of Georgia School of Law, where he was a research assistant for dean Randy Beck and teaching assistant for legal writing professor Jean Mangan.\u0026nbsp; Tyler won the CALI award for legal writing, and was also involved in the Child Endangerment and Sexual Exploitation (CEASE) Clinic.\u0026nbsp; Tyler was a recipient of the First Generation Scholarship and a member of the First Generation Student Association.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding's healthcare practice, Tyler gained significant litigation experience assisting clients successfully navigate commercial disputes in state and federal courts throughout the country.\u003c/p\u003e","slug":"kevin-dysart","email":"tdysart@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":7,"guid":"7.capabilities","index":2,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":3,"source":"capabilities"},{"id":19,"guid":"19.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":740,"guid":"740.smart_tags","index":6,"source":"smartTags"}],"is_active":true,"last_name":"Dysart","nick_name":"","clerkships":[],"first_name":"K.","title_rank":9999,"updated_by":202,"law_schools":[{"id":2190,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"2021-01-01 00:00:00"},"order":2,"pin_order":null,"pin_expiration":null}],"middle_name":"Tyler","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":2,"translated_fields":{"en":{"bio":"\u003cp\u003eTyler Dysart is an associate in the firm\u0026rsquo;s Healthcare practice group. Tyler represents hospitals and other clients\u0026nbsp;in the healthcare and life sciences industries involved in complex litigation, arbitration, government investigations, and transactions.\u0026nbsp; Tyler routinely advises on the complex regulatory, contractual, and other commercial issues affecting these entities.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eTyler graduated\u0026nbsp;\u003cem\u003ecum laude\u003c/em\u003e\u0026nbsp;from the University of Georgia School of Law, where he was a research assistant for dean Randy Beck and teaching assistant for legal writing professor Jean Mangan.\u0026nbsp; Tyler won the CALI award for legal writing, and was also involved in the Child Endangerment and Sexual Exploitation (CEASE) Clinic.\u0026nbsp; Tyler was a recipient of the First Generation Scholarship and a member of the First Generation Student Association.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding's healthcare practice, Tyler gained significant litigation experience assisting clients successfully navigate commercial disputes in state and federal courts throughout the country.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12127}]},"capability_group_id":2},"created_at":"2026-02-11T20:20:03.000Z","updated_at":"2026-02-11T20:20:03.000Z","searchable_text":"Dysart{{ FIELD }}Tyler Dysart is an associate in the firm’s Healthcare practice group. Tyler represents hospitals and other clients in the healthcare and life sciences industries involved in complex litigation, arbitration, government investigations, and transactions.  Tyler routinely advises on the complex regulatory, contractual, and other commercial issues affecting these entities.\nTyler graduated cum laude from the University of Georgia School of Law, where he was a research assistant for dean Randy Beck and teaching assistant for legal writing professor Jean Mangan.  Tyler won the CALI award for legal writing, and was also involved in the Child Endangerment and Sexual Exploitation (CEASE) Clinic.  Tyler was a recipient of the First Generation Scholarship and a member of the First Generation Student Association. \nPrior to joining King \u0026amp; Spalding's healthcare practice, Tyler gained significant litigation experience assisting clients successfully navigate commercial disputes in state and federal courts throughout the country. Associate University of Georgia University of Georgia School of Law University of Georgia University of Georgia School of Law University of Georgia University of Georgia School of Law U.S. District Court for the Northern District of Georgia Georgia","searchable_name":"K. Tyler Dysart","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null}]}}